25985 Efficacy of tildrakizumab 100 mg for PASI improvement in patients with moderate to severe plaque psoriasis: Pooled analysis using nonresponder imputation from reSURFACE 1 and 2 through week 52
2021 ◽
Vol 85
(3)
◽
pp. AB78